CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
CRA consultants named top experts in the 2025 IAM Patent 1000 rankings
Fourteen CRA consultants were recognized as leading economic, financial, and licensing expert witnesses by Intellectual Asset Management (IAM). The IAM Patent...